公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2018 | Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan | Wang, CK; MING-CHIH HO ; Su C.-W.; Wang T.-E.; Dai C.-Y.; CHIEN-HUNG CHEN ; Chen R.-C.; Yang S.-S.; Hung C.-F.; Huang S.-F.; Liao L.-Y.; Huo T.-I.; Wu C.-C.; PO-HUANG LEE ; Ting C.-T.; Lee W.-C.; Chau G.-Y.; Wang C.-C.; Lee K.-T.; Huang Y.-H.; Lin S.-M.; GUAN-TARN HUANG ; Chen K.-Y.; Lin X.-Z.; Hwang J.-I.; Chiou Y.-Y.; Wang C.-K.; Hu J.-T.; Chen S.-C.; PO-CHIN LIANG ; Lee R.-C.; Wu D.-K.; Lin C.-Y.; Lin C.-C.; ANN-LII CHENG ; CHIUN HSU ; Chao Y.; Chen L.-T.; Wang P.-M.; Wang P.-M.; Hong J.-H.; Hsu H.-C.; Chen S.-W.; Leung S.W.; CHIA-HSIEN CHENG ; Wu J.-C.; Wu C.-Y.; Hsu Y.-C.; Hsu C.-W.; YEN-HSUAN NI ; Lin C.-L.; Local ablation group, Surveillance group, Diagnosis group, Staging group, Surgery group, TACE/TARE/HAI group, Target therapy/systemic therapy group, Radiotherapy group, Prevention group, Drafting group; Surveillance group; Diagnosis group; Staging group; Surgery group; TACE/TARE/HAI group; Target therapy/systemic therapy group; Radiotherapy group; Prevention group; Drafting group | Journal of the Formosan Medical Association = Taiwan yi zhi | 90 | 87 | |
2016 | NMR-based metabolomics to determine acute inhalation effects of nano- and fine-sized ZnO particles in the rat lung | Lee S.-H.; Wang T.-Y.; Hong J.-H.; TSUN-JEN CHENG ; CHING-YU LIN | Nanotoxicology | 34 | 29 | |
2016 | Relapse pattern and treatment outcome of curative radiotherapy for primary cutaneous CD30+ anaplastic large-cell lymphoma: A retrospective cohort study | Huang B.-S.; WAN-YU CHEN ; CHUN-WEI WANG ; ANN-LII CHENG ; Hong J.-H.; SUNG-HSIN KUO | Acta Dermato-Venereologica | 3 | 3 | |
2009 | The role of celecoxib in Rad51 expression and cell survival affected by gefitinib in human non-small cell lung cancer cells | JEN-CHUNG KO ; Wang L.-H.; Jhan J.-Y.; Ciou S.-C.; Hong J.-H.; Lin S.-T.; Lin Y.-W. | Lung Cancer | 9 | 9 | |
2008 | Role of repair protein Rad51 in regulating the response to gefitinib in human non-small cell lung cancer cells | JEN-CHUNG KO ; Hong J.-H.; Wang L.-H.; Cheng C.-M.; Ciou S.-C.; Lin S.-T.; Jheng M.-Y.; Lin Y.-W. | Molecular Cancer Therapeutics | 38 | 35 | |
2008 | The role of repair protein Rad51 in synergistic cytotoxicity and mutagenicity induced by epidermal growth factor receptor inhibitor (Gefitinib, IressaR) and benzo[a]pyrene in human lung cancer | JEN-CHUNG KO ; Hong J.-H.; Wang L.-H.; Lin Y.-W. | Experimental Cell Research | 14 | 14 | |